Lesson
Build the Timeline Before the Label
Psychosis is a syndrome with psychiatric, substance, medication, neurologic, and medical causes. Schizophrenia requires a longitudinal diagnosis, not one emergency-room impression.
- Psychosis
- Duration
- Function
- Differential
- First episode
diagnosis first episode
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Define the syndrome
Characterize delusions, hallucinations, disorganized speech or behavior, negative symptoms, catatonia, mood symptoms, cognition, and functional decline. Record onset and duration.
Exclude urgent mimics
Assess delirium, intoxication or withdrawal, neurologic disease, endocrine or metabolic illness, infection, seizures, medications, trauma, mania, depression, and substance-induced psychosis.
Protect the first encounter
Use trauma-informed communication, direct safety assessment, collateral history with consent or emergency authority, and targeted examination and testing.
Use coordinated specialty care
Combine medication, psychotherapy, family education, supported work and education, substance-use care, physical health, and rapid follow-up from the first episode.
Quick check
Lesson
Map More Than Hallucinations
Positive symptoms may respond to dopamine blockade, while negative, cognitive, mood, adverse-effect, trauma, and social domains require separate assessment.
- Positive
- Negative
- Cognitive
- Mood
- Function
symptoms pathways
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Separate symptom domains
Hallucinations, delusions, and disorganization differ from avolition, alogia, blunted affect, cognitive impairment, depression, anxiety, and catatonia.
Use pathways as a model
Mesolimbic D2 blockade may reduce positive symptoms. Nigrostriatal blockade can cause EPS, tuberoinfundibular blockade can raise prolactin, and cortical effects can affect cognition and motivation.
Find secondary negative symptoms
Sedation, parkinsonism, depression, anxiety, social deprivation, substance use, and persistent positive symptoms can resemble primary negative symptoms.
Measure recovery broadly
Track symptoms, function, quality of life, relationships, school or work, cognition, physical health, and patient-defined goals.
Quick check
Lesson
Choose a Drug and a Monitoring Contract
Generation labels do not capture the differences that matter. Prior response, preference, movement, metabolic, prolactin, cardiac, sedation, interaction, organ, and formulation risks guide selection.
- Response
- Preference
- Metabolic
- Movement
- Formulation
selection monitoring
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Use prior history
Identify which drug, dose, duration, adherence, response, and adverse effects were experienced. A failed brief or nonadherent trial is not equivalent to nonresponse.
Build baseline monitoring
Record weight and BMI, waist when used locally, blood pressure, glucose or A1c, lipids, movement examination, sexual and reproductive symptoms, smoking, ECG or prolactin when indicated, and relevant organ function.
Compare individual profiles
Olanzapine and clozapine carry high metabolic burden. Risperidone and paliperidone can raise prolactin. High-potency D2 blockade increases EPS. Ziprasidone and selected agents demand QT attention.
Reassess early and longitudinally
Review efficacy, sedation, orthostasis, movement, akathisia, appetite, weight, glucose, lipids, sexual function, adherence, access, and the patient's own priorities.
Quick check
Lesson
Name the Movement Before Treating It
Acute dystonia, akathisia, parkinsonism, tardive dyskinesia, and neuroleptic malignant syndrome require different responses.
- Dystonia
- Akathisia
- Parkinsonism
- Tardive dyskinesia
- NMS
movement syndromes
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Treat acute dystonia urgently
Painful sustained contractions can involve the jaw, neck, eyes, or airway. Use parenteral anticholinergic or antihistamine rescue when indicated and observe for recurrence.
Recognize akathisia
Subjective inner restlessness with observable movement may resemble anxiety or agitation. Reduce the cause when possible and use a targeted treatment such as propranolol when appropriate.
Separate parkinsonism from TD
Rigidity, bradykinesia, and tremor differ from choreoathetoid or stereotypic tardive movements. Anticholinergics can help selected parkinsonism but can worsen cognition and TD.
Screen for tardive dyskinesia
Use a structured examination, reduce unnecessary dopamine-blocking exposure, and consider valbenazine or deutetrabenazine when clinically appropriate.
Quick check
Lesson
Translate Receptors Into Tradeoffs
FGAs emphasize D2 antagonism, while many SGAs add 5-HT2A and other receptor effects. Partial agonists add another pattern, but no label makes a class uniform.
- D2
- 5-HT2A
- Muscarinic
- Histamine
- Alpha-1
fga sga
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Use potency carefully
Higher-potency FGAs often cause more EPS and prolactin effects, while lower-potency agents often add sedation, orthostasis, anticholinergic effects, and weight burden.
Understand SGA diversity
Clozapine, olanzapine, quetiapine, risperidone, paliperidone, lurasidone, ziprasidone, lumateperone, and others have distinct profiles and indications.
Use partial agonists accurately
Aripiprazole, brexpiprazole, and cariprazine differ in receptor affinity, active metabolites, dosing, and activation or akathisia risk.
Avoid false class rules
Every antipsychotic can cause serious harm. Lower average risk in one domain does not remove the need to monitor the individual.
Quick check
Lesson
Use Clozapine Early Enough and Safely
Clozapine is the standard for treatment-resistant schizophrenia and has specific roles in persistent suicide and aggression risk, but its benefits require whole-system monitoring.
- Treatment resistance
- Suicide
- ANC
- Myocarditis
- Gastrointestinal hypomotility
clozapine
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Recognize the indication
Confirm two adequate antipsychotic trials with adherence and dose evidence. Do not prolong ineffective sequential switching when clozapine is indicated.
Update the access rule
The FDA removed the Clozapine REMS effective June 13, 2025. Enrollment and ANC reporting to REMS are no longer required, but baseline and ongoing ANC monitoring remain recommended under current prescribing information.
Monitor early lethal risks
Use slow titration and assess orthostasis, fever, chest pain, dyspnea, tachycardia, inflammatory or cardiac evidence, seizures, and infection.
Prevent gastrointestinal catastrophe
Ask directly about bowel frequency, pain, distension, nausea, vomiting, and oral intake. Reduce constipating burden and use a proactive bowel plan when appropriate.
Quick check
Lesson
Treat Each LAI as Its Own System
LAIs can improve convenience and make adherence visible, but loading, oral overlap, injection route, interval, missed-dose logic, renal limits, and observation are product specific.
- Preference
- Tolerability
- Loading
- Overlap
- Missed dose
long acting injectables
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Establish tolerability
Confirm oral exposure when the product label requires it and assess prior response, adverse effects, patient preference, injection concerns, and access.
Follow the exact initiation
Paliperidone, risperidone, aripiprazole, olanzapine, haloperidol, and fluphenazine products use different loading, overlap, injection sites, and intervals.
Plan missed doses before they occur
Document the latest dose, exact product, strength, interval, next due date, and product-specific restart rules.
Respect special monitoring
Olanzapine pamoate requires its restricted post-injection observation process. Renal function can limit selected paliperidone products.
Quick check
Lesson
De-escalate, Diagnose, Then Medicate
Agitation can arise from psychosis, mania, delirium, intoxication, withdrawal, trauma, pain, fear, hypoxia, or medication effects.
- De-escalation
- Cause
- Route
- Sedation
- Monitoring
acute agitation
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Start with environment and communication
Reduce stimulation, respect space, offer choices, address basic needs, use one calm communicator, and invite oral treatment when safe.
Match medication to cause
Antipsychotics may fit psychosis or mania. Benzodiazepines may fit stimulant intoxication or alcohol withdrawal but can worsen respiratory depression or delirium in other contexts.
Respect combination warnings
Avoid unsafe temporal proximity of intramuscular olanzapine and parenteral benzodiazepines and account for cumulative sedation, hypotension, and respiratory risk.
Monitor the endpoint
The goal is calm participation and safety, not unconsciousness. Recheck airway, breathing, circulation, temperature, glucose, movement, QT risk, and the evolving diagnosis.
Quick check
Lesson
Make Exposure Changes Visible
Food, smoking, CYP inhibitors and inducers, renal function, dosage form, and administration route can change antipsychotic exposure and safety.
- CYP1A2
- CYP2D6
- CYP3A4
- Food
- Renal function
interactions formulations
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Separate smoke from nicotine
Polycyclic aromatic hydrocarbons in smoke induce CYP1A2. Abrupt smoking cessation can raise clozapine or olanzapine concentrations even if nicotine replacement continues.
Respect food requirements
Lurasidone requires at least 350 calories for reliable exposure. Ziprasidone also requires food. Quetiapine XR and sublingual asenapine have distinct administration instructions.
Map CYP interactions
Strong CYP3A4 inhibitors or inducers can make selected agents unsuitable. CYP2D6 inhibition can increase risperidone exposure. Clozapine has a complex interaction profile.
Use the exact formulation
ODTs, solutions, sublingual tablets, transdermal systems, acute IM products, and LAIs are not automatically dose-equivalent or interchangeable.
Quick check
Lesson
Change the Plan When the Context Changes
Pregnancy, lactation, older age, dementia, Parkinson disease, substance use, organ dysfunction, and homelessness change risk and access.
- Pregnancy
- Dementia
- Parkinson disease
- Substances
- Access
special populations
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Plan perinatal care
Balance relapse risk, prior response, metabolic and obstetric effects, neonatal adaptation, lactation, and patient preference. Do not use obsolete pregnancy letters.
Avoid routine dementia prescribing
Antipsychotics increase mortality in older adults with dementia-related psychosis. Investigate delirium, pain, infection, medications, environment, and nonpharmacologic care first.
Protect movement in Parkinson disease
Pimavanserin treats hallucinations and delusions associated with Parkinson disease psychosis without D2 blockade. Quetiapine or clozapine may be used in selected cases under specialist care.
Treat access as pharmacotherapy
Housing, refrigeration, transport, insurance, injection visits, laboratory access, literacy, stigma, and pharmacy availability determine whether a regimen can work.
Quick check
Lesson
Treat the Life Around the Symptoms
Recovery includes safety, belonging, housing, education, employment, cognition, physical health, relationships, autonomy, and meaning, not only fewer voices.
- CBT for psychosis
- Family
- Supported employment
- Peer support
- Physical health
psychosocial recovery
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
Use coordinated care
First-episode programs combine medication management, psychotherapy, family work, case management, supported work or education, and substance-use treatment.
Support self-management
Teach symptom and adverse-effect recognition, sleep, routines, stress planning, crisis contacts, medication options, and shared decisions without reducing the person to adherence.
Protect physical health
Address smoking, cardiovascular risk, vaccination, dental care, sexual health, cancer screening, movement, nutrition, and access to primary care.
Preserve autonomy
Use supported decision-making, advance preferences, least restrictive care, respectful language, and the person's own goals whenever possible.
Quick check
Lesson
Build One Longitudinal Safety System
Schizophrenia care fails when diagnosis, medications, injections, movement, metabolic results, crisis plans, and functional supports live in disconnected records.
- Target
- Exposure
- Monitoring
- Relapse
- Ownership
integrated plan
Connect symptom domains, treatment tradeoffs, physical health, and recovery.
State current treatment precisely
Record generic drug, formulation, dose, route, schedule, latest LAI date, next due date, oral overlap, indication, response, and adverse effects.
Track the whole trajectory
Follow positive, negative, cognitive, mood, catatonic, functional, substance, metabolic, movement, cardiovascular, and reproductive domains.
Name early relapse signs
Identify each person's changes in sleep, suspiciousness, withdrawal, speech, function, substance use, and medication pattern, plus who should be contacted.
Assign ownership
Specify who monitors laboratory work, injections, clozapine safety, movement, physical health, psychotherapy, social support, and emergency escalation.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.